At the news
? BEARISHIMPACT 5/10 EFFECT filed Jul 17, 2026 at 00:15 ET
Catalyst Pharmaceuticals received SEC effectiveness on July 16, 2026 for four separate shelf registration statements (File Nos. 333-215315, 333-170945, 333-151368, 333-240052, and 333-219259), each previously filed as POS AM amendments. This batch of EFFECT notices confirms the company can now sell securities under multiple shelf registrations at any time, creating a potential dilution overhang. The simultaneous effectiveness of multiple shelves suggests preparation for flexible capital raising, though no specific offering size or timing is disclosed in these filings.
- Four shelf registration statements (File Nos. 333-215315, 333-170945, 333-151368, 333-240052, 333-219259) were declared effective by the SEC on July 16, 2026.
- Each shelf was preceded by a POS AM (post-effective amendment) filing, indicating updates to previously filed registration statements.
- No offering size, pricing, or specific security type is disclosed in these EFFECT notices.
- The company has a $3.9B market cap and analyst consensus is 0% bullish (6 Hold, 1 Sell, 2 Strong Sell).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access